Clinical Study
Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study
Table 4
Antihypertensive medications at baseline and one year.
| | Baseline | 1 year | | Persistent extreme hypertension () | Extreme hypertension at baseline, recovered by 1-year () | Remainder of population () | | Persistent extreme hypertension () | Extreme hypertension at baseline, recovered by 1 year () | Remainder of population () | |
| Number of different antihypertensive medications | 3.2 ± 1.5 | 2.4 ± 1.4 | 2.6 ± 1.3 | 0.19 | 3.4 ± 1.6 | 2.6 ± 1.3 | 2.7 ± 1.3 | 0.14 | Angiotensin blockade | 66% | 58% | 63% | 0.73 | 78% | 66% | 65% | 0.74 | Diuretic | 44% | 26% | 26% | 0.45 | 55% | 24% | 24% | 0.10 | Calcium channel blocker | 11% | 14% | 18% | 0.68 | 11% | 26% | 18% | 0.58 | Beta blocker | 22% | 10% | 10% | 0.51 | 11% | 12% | 10% | 0.94 | Alpha blocker | 0% | 0% | 6% | 0.64 | 0% | 0% | 6% | 0.64 | Vasodilator | 0% | 0% | 0.23% | 0.93 | 0% | 0% | 0.23% | 0.93 | Centrally acting agent | 10% | 0% | 0.4% | 0.001 | 10% | 0% | 0.7% | 0.001 |
|
|
Data are for patients with complete baseline and 1-year medication records.
|